Month: January 2025

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation is scheduled for Wednesday, January 15, 2025, at 8:15 a.m. Pacific Standard Time (PST). The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’...

Appoints Chief Marketing Officer and Senior Vice President – Sales & Business Development, Battery & Energy Products NEWARK, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) — Ultralife Corporation (NASDAQ: ULBI) today announced the appointment of Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President – Sales & Business Development, Battery & Energy Products, effective January 6, 2025. As Chief Marketing Officer, Jeff will be responsible for reframing our corporate and brand strategies, providing alignment and accountability throughout the global organization. He will collaborate closely with our sales and engineering teams to develop and execute effective go-to-market strategies, ensuring that Ultralife’s products and solutions meet the evolving needs of our customers. Jeff brings over two...

LAS VEGAS, Jan. 06, 2025 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC), the global leader in marine technology, will display it’s broad, industry-leading technology portfolio and debut its ‘Boating Intelligence’ initiative at the 2025 Consumer Electronics Show (CES) in Las Vegas.  Boating Intelligence is a comprehensive initiative to enhance Brunswick’s ACES (Autonomous, Connected, Electrified, and Shared) strategy by incorporating AI capabilities and features into its products to deliver simpler, safer, smarter, and more sustainable boating. Brunswick’s CES exhibit will seamlessly integrate digital and physical elements: a state-of-the-art 200-degree virtual boat helm simulator will introduce Brunswick’s AI-powered co-captain, offering an interactive experience that showcases features such as assisted navigation, safety...

WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) — Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed Chief Executive Officer of the subsidiary, to be named Cyncado TherapeuticsTM, Inc. As CEO, Mr. Molloy will lead efforts to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A2a and A2b receptor antagonists. These therapeutics are distinguished by their potency, selectivity, and optimized binding characteristics, designed to enable robust and sustained inhibition of immune suppression...

HAMILTON, BERMUDA, January 6, 2025 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today announced that the Company has purchased 1,481,383 of its own shares in the open market, equivalent to 0.9% of its outstanding shares, at an average price of $8.8899. The shares were purchased during December 2024 and have been retired upon receipt. About DHT Holdings, Inc.DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our integrated management companies in Monaco, Norway, Singapore, and India. You may recognize us by our renowned business approach as an experienced organization with focus on first rate operations and customer service; our quality ships; our prudent capital structure that promotes staying power through the business cycles;...

        Company Announcement No 01/2025Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk6 January 2025  Dear Sirs Sydbank share buyback programme: transactions in week 01On 28 February 2024 Sydbank announced a share buyback programme of DKK 1,200m. The share buyback programme commenced on 4 March 2024 and will be completed by 31 January 2025. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share...

First and only medicine approved in the EU for paediatric patients aged 6-months to 5 years old with HoFH, an ultrarare, inherited form of high cholesterol BASEL, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged 6-months and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza, an angiopoietin-like 3 (ANGPTL3) inhibitor, is the first medicine indicated for children in the European Union (EU) as young as 6-months old to treat HoFH, a disease associated with dangerously...